CN Mobile Logo


Radiation Oncology

Radiation Oncology

For men with prostate cancer undergoing radiation therapy, consumption of men’s health supplements are unlikely to prevent adverse events, metastasis, or cancer-related death.

A treatment strategy including dose intensification with interval compression, use of the most active agents available, and the use of irinotecan as a radiation sensitizer led to a promising event-free survival rate in certain patients with metastatic rhabdomyosarcoma.

Hypofractionated radiation therapy appears to lead to similar efficacy and safety as a standard radiation therapy regimen for men with low-risk prostate cancer.

Melanoma has historically been considered a radioresistant tumor. Emerging data have challenged this viewpoint. The potential roles of radiation therapy in the treatment of patients with melanoma will be reviewed here.

It is incumbent on melanoma and radiation oncology researchers alike to further our understanding of when and how RT can help patients.

Current data challenge the statement that recommendations for postmastectomy radiotherapy should be based on the highest clinical or pathologic stage. Instead, data suggest that in a majority of patients, the pathologic stage after neoadjuvant chemotherapy carries more prognostic value.

Hypofractionated radiation therapy results in less toxicity and provides a better quality of life compared with conventional whole-breast irradiation, according to two recent studies.


Subscribe to Radiation Oncology on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.